(Q30899756)

27 June 2017

title

Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes (English)

1 reference

27 June 2017

0 references

4

Michael Hallek

1 reference

27 June 2017

Stephan Maersch

1

1 reference

27 June 2017

Anke Huber

series ordinal

2

1 reference

27 June 2017

Hildegard Büning

series ordinal

3

1 reference

27 June 2017

Luca Perabo

series ordinal

5

1 reference

27 June 2017

language of work or name

English

0 references

publication date

18 November 2009

1 reference

27 June 2017

1 reference

27 June 2017

volume

397

1 reference

27 June 2017

issue

1

1 reference

27 June 2017

page(s)

167-175

1 reference

Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Synoviocyte infection with adeno-associated virus (AAV) is neutralized by human synovial fluid from arthritis patients and depends on AAV serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Recent developments in adeno-associated virus vector technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Immune responses to adenovirus and adeno-associated virus in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Recombinant adeno-associated virus for muscle directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Identification of a heparin-binding motif on adeno-associated virus type 2 capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

DNA shuffling of adeno-associated virus yields functionally diverse viral progeny

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Clinical gene therapy using recombinant adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

In vitro selection of viral vectors with modified tropism: the adeno-associated virus display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Immune responses to adeno-associated virus and its recombinant vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Adeno-associated virus serotypes: vector toolkit for human gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.10.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2009.10.021

1 reference

27 June 2017

1 reference